- Home
- LXEO vs TLRY Comparison
LXEO vs TLRY Comparison
Compare LXEO & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | TLRY |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.3M | 866.8M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LXEO | TLRY |
|---|---|---|
| Price | $6.59 | $7.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $18.60 | ★ $103.33 |
| AVG Volume (30 Days) | 911.2K | ★ 3.6M |
| Earning Date | 03-23-2026 | 01-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $837,323,000.00 |
| Revenue This Year | N/A | $7.39 |
| Revenue Next Year | N/A | $4.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.98 |
| 52 Week Low | $1.45 | $3.51 |
| 52 Week High | $10.99 | $23.20 |
Technical Indicators
Market Signals| Indicator | LXEO | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 42.45 |
| Support Level | $6.73 | $6.97 |
| Resistance Level | $7.31 | $8.31 |
| Average True Range (ATR) | 0.46 | 0.43 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 17.16 | 25.67 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.